Liver Test Study of Using JKB-122 in AIH Patients



Status:Active, not recruiting
Conditions:Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:9/14/2018
Start Date:February 2016
End Date:December 2018

Use our guide to learn which trials are right for you!

A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks in subjects
with autoimmune hepatitis (AIH) who have liver enzymes that are 1.25 to 10 times the upper
limit of normal (ULN) and who have had a failed response to, incomplete response to,
intolerant to, ineligible to, or unwilling to take current immunosuppressant therapies. The
dose of JKB-122 will be escalated monthly.

This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks to subjects
with AIH who have liver enzymes that are 1.25 to 10 times the upper limit of normal (ULN) and
who have had a failed response to, incomplete response to, intolerant to, ineligible to or
unwilling to take current immunosuppressant therapies. Current immunosuppressant therapy is
defined as prednisone or other steroids with or without azathioprine. Failed response is
defined as being non-responsive to or worsening in symptoms (elevated Alanine
Aminotransferase (ALT)/aspartate aminotransferase (AST) and/or total bilirubin) despite
compliance with the standard of care (SOC) over a 6 months period. Incomplete response is
defined as lack of a sustained normalization of elevated ALT/AST to current standard of care
(SOC) for at least 6 months. "Refractory" to the current therapy includes patients who had a
failed response to, or incomplete response to the current therapy.

Subjects will be at least 18 years of age, either male or female and will have been on
therapy for AIH and have not had a normalization of ALT with the current therapy.

Inclusion Criteria:

- Has definite or probable AIH diagnosis.

- Has had a liver biopsy or Fibroscan™ within 3 years and the severity of hepatic
dysfunction is limited to the following:

- Metavir Stage 0 to stage 3 fibrosis (according to liver biopsy) or Fibroscan™
results

- ALT and AST values not exceeding 10x ULN

- Normal bilirubin and prothrombin time (PT/INR)

- Has elevated liver test results (ALT) at least 1.25 x ULN and not exceeding 10 x ULN
at baseline.

- Has had a failed response, incomplete response, intolerant, ineligible or unwilling to
take current immunosuppressive therapies. Current immunosuppressive therapy is defined
as prednisone or other steroids with or without azathioprine.

Exclusion Criteria:

- Has history of allergy to JKB-122 or related compounds

- Has human immunodeficiency virus (HIV) or is hepatitis B virus or hepatitis C virus
(HCV) positive

- Has positive urine drug screen at Screening

- Has been diagnosed with other overlapping liver diseases such as primary biliary
cirrhosis (PBC) or primary sclerosing cholangitis (PSC)

- Is currently consuming alcoholic drinks greater than 25g/day and within 3 months prior
to the first screening visit.

- Is being treated with any prescription narcotic drug (including transdermal delivery
systems)

- Concurrent medications within 30 days prior to screening:

- Opioids

- Thioridazine

- Silymarin and related medications

- Potentially hepatotoxic drugs

- Has a known or suspected central nervous system disorder that may predispose to
seizures or lower the seizure threshold

- Has unstable and uncontrollable hypertension (>180/110 mmHg) or a blood pressure
reading at baseline of 150/90 mmHg on 2 occasions separated by a 30 minute interval

- Is currently receiving dietary supplements other than a multivitamin to treat AIH

- Has received other investigational agents within 90 days prior to the first screening
visit

- Has impaired renal function

- Has malignancy.

- If female, pregnant or lactating

- Has history of gastroesophageal varices, ascites, hepatic encephalopathy,
hepatocellular carcinoma, and s/p liver transplantation
We found this trial at
16
sites
New Orleans, Louisiana 70112
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Principal Investigator: Charles Landis
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Steven Flamm
Phone: 312-694-1293
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75203
Principal Investigator: Parvez Mantry
Phone: 214-947-4446
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Andrew Muir
Phone: 919-970-1724
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Gainesville, Florida 32610
Principal Investigator: Giuseppe Morelli
Phone: 352-273-9464
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: John Vierling
Phone: 832-355-8708
?
mi
from
Houston, TX
Click here to add this to my saved trials
340 W 10th St #6200
Indianapolis, Indiana 46202
(317) 274-3772
Principal Investigator: Craig Lammert
Phone: 317-278-3584
Indiana University School of Medicine With more than 2,000 students in 2013, the Indiana University...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
5901 West Olympic Boulevard
Los Angeles, California 90036
Principal Investigator: Peter Ruane
Phone: 323-954-0400
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Joseph Odin
Phone: 212-241-0493
?
mi
from
New York, NY
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Christopher Bowlus
Phone: 916-734-8696
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
San Antonio, Texas 78215
Principal Investigator: Eric Lawitz, MD
Phone: 210-253-3426
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Antonio, Texas
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
45 Castro Street
San Francisco, California 94114
(415) 600-6000
California Pacific Medical Center California Pacific Medical Center is one of the largest private, not-for-profit,...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Erik Ness
Phone: 1-206-386-3201
?
mi
from
Seattle, WA
Click here to add this to my saved trials